Global Cancer Diagnostics Market Size By Diagnostic Type (Biopsy And Cytology Tests, Diagnostic Imaging Tests), By Cancer Type (Breast Cancer, Leukemia), By Geographic Scope And Forecast

Cancer Diagnostics Market Size And Forecast

Cancer Diagnostics Market size was valued at USD 111.70 Billion in 2024 and is projected to reach USD 188.43 Billion by 2031 , growing at a CAGR of 6.77% during the forecast period 2024-2031. The global Cancer Diagnostics Market has witnessed strong growth owing to the increasing technological advancements in various fields such as biomarkers, imaging, etc., a growing number of cancer cases, rapid growth in the geriatric population, awareness actions by governments, and growing government funding. The Global Cancer Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cancer Diagnostics Market Definition

Cancer is one of the most popular comprehensive diseases in the world. The process of detecting cancer includes the usage of certain technology and devices specifically used in its diagnosis. Cancer deaths can be prevented and controlled due to proper and prior diagnosis. A cancer diagnosis is defined as the identification of cancer in patients who have developed the signs of the disease. Early diagnosis leads to effective treatment and secures the survival chances of the patient. Effective diagnostic testing is practiced to confirm or exclude the presence of disease, monitor the disease process, and plan for and decide the effectiveness of treatment.

In some cases, it is important to repeat testing when a person's condition has improved, if a sample received was not of good quality, or if an abnormal test result needs to be confirmed. Diagnostic ways for cancer may involve imaging, laboratory tests (including inspections for tumor markers), tumor biopsy, endoscopic examination, surgery, or genetic testing. Cancer diagnosis begins with a physical checkup. The detection of certain biomarkers and proteins that are common in cancer disorders thereby, results in the diagnosis process. Remarkable another process of detecting cancer includes the usage of certain technology and devices particularly used in its diagnosis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cancer Diagnostics Market Overview

The global Cancer Diagnostics Market is principally driven by the continual introduction of innovative products, coupled with a growing need for early diagnosis of various diseases. Also, the rapid growth of the healthcare and diagnostics sector can be assigned to the entrance of technologically advanced laboratory systems that have updated oncological screening in producing reliable results. The increasing incidence of cancer is triggering the market for these screening tests and imaging modalities used for observing disease progression, thereby driving the market growth.

According to the World Health Organization (WHO), cancer was the second-leading reason for death globally, subject to approximately 9.6 million deaths in 2018. The National Cancer Insititute (NCI) has determined the number of new cancer cases per year reaches 23.6 million by 2030. Moreover, R&D in cancer diagnostics is also anticipated to aid in the growth of the market. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported an assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 - a major protein splice variant is forms expressed in human gastrointestinal cancer cells-by monoclonal antibodies.

However, inadequate reimbursement policies are expected to hinder the growth of the market. There have been various advancements in radiology about imaging equipment in the recent past. Most medical insurance companies do not provide reimbursement for procedures utilizing Computer-aided Detection (CAD). Moreover, the high price of cancer detection software is also anticipated to hinder the growth of the market. Computer-aided detection (CAD) software is available with a one-year license and hospitals to have to renew it every year. Nonetheless, the development of biopsy platforms for associate animal cancers is expected to offer profitable growth opportunities for players in the global Cancer Diagnostics Market. Moreover, the use of AI in quick detection of cancer is also supposed to aid in the growth of the market.

Global Cancer Diagnostics Market Segmentation Analysis

The Global Cancer Diagnostics Market is segmented based on Diagnostic Type, Cancer Type, and Geography.

Cancer Diagnostics Market, By Diagnostic Type

• Biopsy and Cytology Tests
• Diagnostic Imaging Tests
• Endoscopy
• Genetic Tests
• Others
• Based on Diagnostic Type, the market is bifurcated into Biopsy and Cytology Tests, Diagnostic Imaging Tests, Endoscopy, Genetic Tests, and Others. The Diagnostic Imaging Tests segment has dominated the major market share and is estimated to witness the highest CAGR for the forecast period. Imaging modalities such as Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) are fast, non-invasive, and pain-free diagnostic explications. These imaging modalities are applied as supportive tests along with other laboratory and genetic tests to discover the location and sharpness of the condition in diagnosing a different type of cancer, thereby helping in the choice of a suitable treatment regimen

Cancer Diagnostics Market, By Cancer Type

• Breast Cancer
• Leukemia
• Pancreatic Cancer
• Prostate Cancer
• Colon and Rectal Cancer
• Others

Based on Cancer Type, the market is bifurcated into Breast Cancer, Leukemia, Pancreatic Cancer, Prostate Cancer, Colon and Rectal Cancer, and Others. The Breast Cancer segment is estimated to witness the highest CAGR for the forecast period. The significant causes leading to an upsurge in breast cancer prevalence and percentage rates are hormone replacement therapy, obesity, reduced childbearing and age-related dangers. Transforming lifestyles and increased drink consumption can be directly linked with breast cancer prevalence as well as measure, as it results in an increase in estrogen levels in the body.

Cancer Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world.

Based on Regional Analysis, the Global Cancer Diagnostics Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominated the market by capturing the largest revenue share and is expected to continue its lead throughout the forecast period owing to factors such as more prominent funding available for research and development plans and the huge adoption of advanced technologies. The presence of various biotechnology as well as medical device companies in this region is also one of the principal factors driving the diagnostics sector in the region. The Asia Pacific is also expected to grow at a significant rate due to the availability of skilled technicians at a comparatively lower price and a defined regulatory framework favoring advanced product approvals.

Key Players

• The "Global Cancer Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Illumina, Inc., Koninklijke Philips N.V., Agilent Technologies, Inc., General Electric Company, F. Hoffmann-La Roche Ltd, and Becton, Dickinson, and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• Product Launches and Merchandise Expansions
• In Nov 2021, Becton, Dickinson, and Co., a key medical devices company, launched a machine-controlled high-throughput diagnostic system for cervical cancer screening, dubbed the Bachelor of Divinity COR PX/GX System.
• In August 2021, the system Approved by the U.S. Food and Drug Administration has been designed to be used in centralized labs and might handle the high-volume process with exaggerated potency.
• Partnerships, Collaborations, and Agreements
• In 2020, GE aid entered a partnership with GenesisCare to boost patient outcomes for the 2 biggest health burdens globally, cancer and cardiovascular disease. GE aid can give CT, MRI, PET/CT, SPECT, digital diagnostic techniques, and ultrasound instrumentation to GenesisCare's 440+ cancer and upset treatment centers across Australia, the US, the UK, and Spain.
• In 2020, Roche medicine entered a partnership with Illumina to supply broad access to clinical medical specialty next-generation sequencing.
• Mergers and Acquisition
• In March 2021, Agilent Technologies INC. nonheritable Resolution natural science, to bolster its headship position in cancer medicine.
• In September 2020, Illumina, Inc.'s nonheritable goblet launched a brand-new section of cancer diagnosing. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosing tests with the possibility to observe a lot of cancers earlier and alter higher outcomes.